Proteus Digital Health, Inc

proteus.com

Welcome to Proteus Digital Health, a leading innovator spearheading the Digital Medicines revolution. Join our unique collection of innovative engineers, scientists, designers, developers, clinicians, and other digital health pioneers, and assist us with achieving our compelling vision, “Healthcare for Everyone, Everywhere.” Proteus is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicine includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making, and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicine is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

news image

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More

PHARMACY MARKET

BUSHU PHARMA'S PARTNERSHIP WITH SUZUKEN GROUP INCREASES SPECIALTY PHARMACEUTICAL SERVICES

Bushu Pharmaceuticals Ltd. | April 28, 2021

news image

Bushu Pharmaceuticals Ltd. has entered into a business partnership arrangement with Suzuken Co., Ltd. to provide specialty pharmaceutical producers looking to enter the Japanese market with extensive support for new product releases. In recent years, the market has seen an increase in the number of innovative specialty pharmaceuticals, such as biopharmaceuticals, regenerative medicines, and orphan drugs for rare diseases, that require strict temperature, inventory, and security co...

Read More

PHARMACY MARKET

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

news image

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More

PHARMA SALESFORCES BROUGHT TO A HALT AS CORONAVIRUS SHUTTERS ECONOMY

BioPharma Dive: | March 17, 2020

news image

Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...

Read More
news image

TACKLING THE INNOVATION CRISIS IN DRUG DISCOVERY AND DEVELOPMENT

Technology Networks | February 17, 2020

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Read More
news image

PHARMACY MARKET

BUSHU PHARMA'S PARTNERSHIP WITH SUZUKEN GROUP INCREASES SPECIALTY PHARMACEUTICAL SERVICES

Bushu Pharmaceuticals Ltd. | April 28, 2021

Bushu Pharmaceuticals Ltd. has entered into a business partnership arrangement with Suzuken Co., Ltd. to provide specialty pharmaceutical producers looking to enter the Japanese market with extensive support for new product releases. In recent years, the market has seen an increase in the number of innovative specialty pharmaceuticals, such as biopharmaceuticals, regenerative medicines, and orphan drugs for rare diseases, that require strict temperature, inventory, and security co...

Read More
news image

PHARMACY MARKET

SANOFI'S HOPES FOR RARE BLOOD DISEASE CANDIDATE SUTIMLIMAB ON HOLD AFTER FDA BLASTS 3RD-PARTY MANUFACTURER

Sanofi | November 17, 2020

When a new drug goes in front of the FDA for consideration, a lot of moving pieces must be in place for a successful review—manufacturing standards included. That didn't happen for Sanofi, which is pressing pause on a rare disease candidate after the FDA found issues at a contract manufacturer's plant. The FDA blasted a third-party manufacturer of Sanofi's rare blood disease drug sutimlimab in a complete response letter, citing "certain deficiencies" at...

Read More
news image

PHARMA SALESFORCES BROUGHT TO A HALT AS CORONAVIRUS SHUTTERS ECONOMY

BioPharma Dive: | March 17, 2020

Late last year, New Jersey drugmaker Amarin won a long-sought U.S. approval for its pill Vascepa, allowing the company to market the drug for reducing heart risk. It was a major milestone for the company, validating the decision to run a lengthy and expensive cardiovascular outcomes study, which had delivered positive results in 2018. Eager to sell the drug to a now much wider group of patients, Amarin doubled the number of sales representatives it employs to reach out to doctors and other healt...

Read More